Login to Your Account

Imbruvica Gets an FDA Nod in Mantle Cell Lymphoma

By Marie Powers
Staff Writer

Wednesday, November 13, 2013

The FDA gave drug developers good news Wednesday afternoon with the approval of Imbruvica (ibrutinib), the oral Bruton’s tyrosine kinase (BTK) inhibitor developed by Pharmacyclics Inc. and Johnson & Johnson unit Janssen Biotech Inc., as a single agent to treat patients with mantle cell lymphoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription